trial

The Efficacy of REHACOP Program in Schizophrenia

NCTId NCT02796417
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 111 (actual)
Sponsored by University of Deusto
Primary completion 2014-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
111 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2012-03
Primary completion
2014-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
REHACOPOccupational activities

Sponsors

University of DeustoLead Sponsor

Investigators

1
Natalia Ojeda, PhDPrincipal Investigator

Sites

1 total
Bilbao, Spain

Facts & assertions

4 sourced
Enrollment
111
Phase
NA
Primary Completion Date
2014-04
Status
COMPLETED
relationships
The graph out of here
drug
REHACOP
drug
Occupational activities
drug
lead_sponsor
University of Deusto
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Natalia Ojeda, PhD
person